Implanet SA Cash Flow Conversion Efficiency
Implanet SA cash flow conversion efficiency. Based on the latest financial reports, Implanet SA (ALIMP) has a cash flow conversion efficiency ratio of -0.700x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-283.00K ≈ $-330.86K USD) by net assets (€404.00K ≈ $472.32K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Implanet SA (2012–2025)
Cash flow conversion efficiency of Implanet SA from 2012 to 2025. This chart illustrates how Implanet SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Implanet SA for real-time trading data and today's change.
Implanet SA Cash Flow Conversion Ratio Explained
Implanet SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Implanet SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Implanet SA ranked by their cash flow conversion efficiency. Also see Implanet SA stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brookside Energy Ltd
AU:BRK
|
0.108x |
|
Comelf SA
RO:CMF
|
0.044x |
|
Team Young Advanced Technology Co Ltd
TWO:5345
|
0.046x |
|
Yukselen Celik As
IS:YKSLN
|
0.232x |
|
Renewables Infrastructure Grp
LSE:TRIG
|
0.022x |
|
KNW Co. Ltd
KQ:105330
|
0.026x |
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
0.211x |
|
FibroBiologics, Inc. Common Stock
NASDAQ:FBLG
|
-31.776x |
Annual Cash Flow Conversion Efficiency for Implanet SA (2012–2025)
The table below shows the annual cash flow conversion efficiency of Implanet SA from 2012 to 2025. Review how much free cash does Implanet SA generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €404.00K ≈ $472.32K |
€-589.00K ≈ $-688.60K |
-1.458x | +54.39% |
| 2024-12-31 | €727.00K ≈ $849.94K |
€-2.32 Million ≈ $-2.72 Million |
-3.197x | -138.44% |
| 2023-12-31 | €-174.00K ≈ $-203.42K |
€-1.45 Million ≈ $-1.69 Million |
8.316x | +1324.93% |
| 2022-12-31 | €3.54 Million ≈ $4.14 Million |
€-2.40 Million ≈ $-2.81 Million |
-0.679x | +45.84% |
| 2021-12-31 | €2.80 Million ≈ $3.28 Million |
€-3.52 Million ≈ $-4.11 Million |
-1.254x | +58.26% |
| 2020-12-31 | €1.02 Million ≈ $1.19 Million |
€-3.07 Million ≈ $-3.59 Million |
-3.003x | -53.51% |
| 2019-12-31 | €1.44 Million ≈ $1.68 Million |
€-2.81 Million ≈ $-3.28 Million |
-1.956x | -5.80% |
| 2018-12-31 | €2.40 Million ≈ $2.81 Million |
€-4.44 Million ≈ $-5.19 Million |
-1.849x | -160.38% |
| 2017-12-31 | €6.29 Million ≈ $7.35 Million |
€-4.46 Million ≈ $-5.22 Million |
-0.710x | -16.42% |
| 2016-12-31 | €9.66 Million ≈ $11.29 Million |
€-5.89 Million ≈ $-6.89 Million |
-0.610x | +12.91% |
| 2015-12-31 | €9.73 Million ≈ $11.37 Million |
€-6.81 Million ≈ $-7.96 Million |
-0.700x | +4.55% |
| 2014-12-31 | €7.21 Million ≈ $8.43 Million |
€-5.29 Million ≈ $-6.19 Million |
-0.734x | -88.93% |
| 2013-12-31 | €13.87 Million ≈ $16.21 Million |
€-5.39 Million ≈ $-6.30 Million |
-0.388x | +54.44% |
| 2012-12-31 | €4.68 Million ≈ $5.47 Million |
€-3.99 Million ≈ $-4.66 Million |
-0.852x | -- |
About Implanet SA
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-… Read more